Progenics Pharmaceuticals, Inc.
http://www.progenics.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Progenics Pharmaceuticals, Inc.
Aerie Misses Quick Path To Dry Eye Approval, But Is Still Moving Forward
AR-15512 missed the primary endpoints in a Phase IIb dry eye disease study that could have served as a pivotal trial, but Aerie’s drug hit enough signs and symptoms of the disease to justify a Phase III.
AAOS 2021: Digital Tools In Surgical Ecosystem, Software-Enabled Tech, Robots, Wearables, Sensors
At the live AAOS conference, exhibitors, including major orthopedics players, demoed digital innovations, software-enabled technologies, robotics and smart implants that are expected to create efficiencies in the surgical continuum and provide data to improve outcomes.
Finance Watch: The Bigger The Better? Erasca, Imago Rise After IPOs
Public Company Edition: Three $100m-plus US initial public offerings launched on 15 July after two smaller biopharma IPOs earlier in the month. Also, Gelesis announced a SPAC merger, Brii and Amniotics launched ex-US IPOs, and Intellia, Cerevel and Kymera priced large follow-on offerings.
Frontrunner Kymera Claims Proof-Of-Concept For Protein Degrader Platform
Kymera has unveiled the first placebo-controlled data from a protein degradation candidate, adding to heightened expectations for the novel modality.
Company Information
- Industry
- Biotechnology
- Digital Health
- Pharmaceuticals
-
Pharmaceuticals
- Radiopharmaceuticals, Contrast Agents
-
Medical Devices
-
Diagnostic Imaging Equipment & Supplies
- Molecular Imaging
-
Diagnostic Imaging Equipment & Supplies
-
Biotechnology
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- ADMET
-
Large Molecule
- Other Names / Subsidiaries
-
- Molecular Insight Pharmaceuticals, Inc.
- PSMA Development Company
- UR Labs (URL)